We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Filtration Method Developed for Cord Blood

By LabMedica International staff writers
Posted on 27 Dec 2012
A novel filtration system using a nonchemical-coated and nonwoven polyester fabric filter, which traps cells through affinity, has been developed for cord blood. More...


Cord blood (CB) is being increasingly used as a source of hematopoietic stem cells for transplantation to treat diseases of the blood and immune systems, and there is an urgent need to expand CB banking worldwide.

Scientists at Kyushu University School of Medical Science (Fukuoka, Japan) developed a polyester fabric filter specifically for CB, which traps cells and does not require centrifugation or potentially toxic chemicals. Normally CB processing requires costly machinery or a clean room that hampers wider application of cord blood transplantation (CBT) particularly in the developing countries.

The collection efficacy was calculated by counting total nucleated cells (TNCs) using an automated hematology analyzer KX-21 (Sysmex; Kobe, Japan) or ABX Pentra hematology analyzer (Horiba; Kyoto, Japan). The red blood cell (RBC) compartment combines the RBCs and the nucleated red cells. The number of mononuclear cells (MNCs) or polymorphonuclear cells (PMNs) was calculated as the product of TNC count, and the percentage of each population analyzed by FACSCanto flow cytometry (BD Biosciences; San Jose, CA, USA). Collection efficacy was defined as the ratio of cell number in the collected fraction relative to the introduced cord blood.

The loss of TNCs, MNCs, and PMNs was less than 5%. The loss of CD34+ cells was only 0.5%, indicating the minimal loss of nucleated cells and CD34+ cells during this process. On the other hand, 84.8% of RBCs and 61.0% of platelets were in the flow-through fraction. These data indicated that the device could trap nucleated cells and remove RBCs and platelets efficiently. Therefore cell processing with the device resulted in minimum cell loss of total cells and CD34+ cells, without impairing the ability of CD34+ cells to engraft and differentiate both in vivo and in vitro.

The authors concluded that CB processing with the device is simple, cost-effective, and nontoxic without requiring costly equipment will facilitate international CB banking. This will help in meeting the increasing worldwide demand for CB for allogeneic hematopoietic stem cell transplantation. The study was published on December 14, 2012, in the International Journal of Laboratory Hematology.

Related Links:
Kyushu University School of Medical Science
Sysmex
Horiba



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Rapid Flu Test
Influenza A&B Rapid Test Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.